The Safety, Tolerability and Preliminary Efficacy of Derived Motor Neuron Progenitor Cells (XS228CN) in Subjects With Amyotrophic Lateral Sclerosis

NCT07118319 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Amyotrophic Lateral Sclerosis (ALS)

Interventions

DRUG: Human Allogeneic Induced Pluripotent Stem Cells (iPSCs) -Derived Motor Neuron Progenitor Cells (XS228CN)
DRUG: Human Allogeneic Induced Pluripotent Stem Cells (iPSCs) -Derived Motor Neuron Progenitor Cells (XS228CN)

Sponsor

XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.